A randomized, double-blind, placebo-controlled three-period incomplete cross over study to compare the efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis using an Environmental Exposure Chamber

Trial Profile

A randomized, double-blind, placebo-controlled three-period incomplete cross over study to compare the efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis using an Environmental Exposure Chamber

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Fevipiprant (Primary) ; Montelukast
  • Indications Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2014 New source identified and integrated (German Clinical Trials Register; DRKS00005517).
    • 27 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Sep 2013 Planned number of patients changed from 190 to 570 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top